JP2015524825A - Ｖｅｇｆｒ３阻害剤 - Google Patents
Ｖｅｇｆｒ３阻害剤 Download PDFInfo
- Publication number
- JP2015524825A JP2015524825A JP2015526835A JP2015526835A JP2015524825A JP 2015524825 A JP2015524825 A JP 2015524825A JP 2015526835 A JP2015526835 A JP 2015526835A JP 2015526835 A JP2015526835 A JP 2015526835A JP 2015524825 A JP2015524825 A JP 2015524825A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- methyl
- group
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C/C1=C(/N*)\N=C\C(\*)=C(/CC*)\CC1 Chemical compound C/C1=C(/N*)\N=C\C(\*)=C(/CC*)\CC1 0.000 description 25
- GDTPIGQXNMUFMV-UHFFFAOYSA-N C#Cc1c(CC(N)=O)cccc1 Chemical compound C#Cc1c(CC(N)=O)cccc1 GDTPIGQXNMUFMV-UHFFFAOYSA-N 0.000 description 1
- LJYZJLBHZHCVRA-UHFFFAOYSA-N CC(C)(C)OC(C(CCC1)CCC1c(ccc(NC1=C=CC(C#Cc2c(CC(OC)=O)cccc2)=C(C(F)(F)F)C=N1)c1)c1F)=O Chemical compound CC(C)(C)OC(C(CCC1)CCC1c(ccc(NC1=C=CC(C#Cc2c(CC(OC)=O)cccc2)=C(C(F)(F)F)C=N1)c1)c1F)=O LJYZJLBHZHCVRA-UHFFFAOYSA-N 0.000 description 1
- COSFOVMGZQVLTK-UHFFFAOYSA-N CC(C)(C)OC(CCC(CC1)CCC1c(ccc(NC1=C=CC(Cl)=C(C(F)(F)F)C=CC1=C)c1)c1F)=O Chemical compound CC(C)(C)OC(CCC(CC1)CCC1c(ccc(NC1=C=CC(Cl)=C(C(F)(F)F)C=CC1=C)c1)c1F)=O COSFOVMGZQVLTK-UHFFFAOYSA-N 0.000 description 1
- YRLQFRXDWBFGMK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c(cc1)ccc1N)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c(cc1)ccc1N)=O YRLQFRXDWBFGMK-UHFFFAOYSA-N 0.000 description 1
- JYTFREFXHAFMQV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c(ccc(N)c1)c1F)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c(ccc(N)c1)c1F)=O JYTFREFXHAFMQV-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N CC(C)(C)OC(N1CC=C(B2OC(C)(C)C(C)(C)O2)CC1)=O Chemical compound CC(C)(C)OC(N1CC=C(B2OC(C)(C)C(C)(C)O2)CC1)=O VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- ODIQTOYGORNLPE-UHFFFAOYSA-N CC(C)N1CCN(C)CC1 Chemical compound CC(C)N1CCN(C)CC1 ODIQTOYGORNLPE-UHFFFAOYSA-N 0.000 description 1
- WHKWMTXTYKVFLK-UHFFFAOYSA-N CC(C)N1CCNCC1 Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
- COSXQRGJLFEFGJ-UHFFFAOYSA-N CC(c(cc1)ccc1N)NC(OC(C)(C)C)=O Chemical compound CC(c(cc1)ccc1N)NC(OC(C)(C)C)=O COSXQRGJLFEFGJ-UHFFFAOYSA-N 0.000 description 1
- QRWTZHKLKHTWCL-UHFFFAOYSA-N CC(c(cc1)ccc1Nc(nc1)nc(CCc2c(CC(N)=O)cccc2)c1Cl)N Chemical compound CC(c(cc1)ccc1Nc(nc1)nc(CCc2c(CC(N)=O)cccc2)c1Cl)N QRWTZHKLKHTWCL-UHFFFAOYSA-N 0.000 description 1
- TXIOGJHPPVXTOY-UHFFFAOYSA-N CCN1CCN(C)CC1 Chemical compound CCN1CCN(C)CC1 TXIOGJHPPVXTOY-UHFFFAOYSA-N 0.000 description 1
- QSWROZWGTVXDSO-UHFFFAOYSA-N COC(Cc(cccc1)c1C#C)=O Chemical compound COC(Cc(cccc1)c1C#C)=O QSWROZWGTVXDSO-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N Clc(cnc(Cl)n1)c1Cl Chemical compound Clc(cnc(Cl)n1)c1Cl GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- IDRUEHMBFUJKAK-UHFFFAOYSA-N FC(c(c(Cl)n1)cnc1Cl)(F)F Chemical compound FC(c(c(Cl)n1)cnc1Cl)(F)F IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 1
- ZWOSDFZIWKFUQW-UHFFFAOYSA-N NC(CC1=CC=CCC1CCc1nc(Cl)ncc1Cl)=O Chemical compound NC(CC1=CC=CCC1CCc1nc(Cl)ncc1Cl)=O ZWOSDFZIWKFUQW-UHFFFAOYSA-N 0.000 description 1
- SMSJVCJPYYIKCG-UHFFFAOYSA-N NC(Cc(cccc1)c1C#Cc1nc(Cl)ncc1Cl)=O Chemical compound NC(Cc(cccc1)c1C#Cc1nc(Cl)ncc1Cl)=O SMSJVCJPYYIKCG-UHFFFAOYSA-N 0.000 description 1
- AZYQMHQOHNGPRR-UHFFFAOYSA-N [O-][N+](c(cc1)cc(F)c1Br)=O Chemical compound [O-][N+](c(cc1)cc(F)c1Br)=O AZYQMHQOHNGPRR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684254P | 2012-08-17 | 2012-08-17 | |
| US61/684,254 | 2012-08-17 | ||
| PCT/AU2013/000912 WO2014026242A1 (en) | 2012-08-17 | 2013-08-16 | Vegfr3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524825A true JP2015524825A (ja) | 2015-08-27 |
| JP2015524825A5 JP2015524825A5 (enExample) | 2016-10-06 |
Family
ID=50101125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526835A Pending JP2015524825A (ja) | 2012-08-17 | 2013-08-16 | Ｖｅｇｆｒ３阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9266864B2 (enExample) |
| EP (1) | EP2885292A4 (enExample) |
| JP (1) | JP2015524825A (enExample) |
| CN (2) | CN104837835A (enExample) |
| AU (1) | AU2013302319A1 (enExample) |
| CA (1) | CA2882270A1 (enExample) |
| HK (1) | HK1209104A1 (enExample) |
| WO (1) | WO2014026242A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015123722A1 (en) * | 2014-02-19 | 2015-08-27 | Bionomics Limited | Inhibitors |
| CN112972492B (zh) | 2015-12-16 | 2024-11-08 | 沃尔特及伊莱萨霍尔医学研究院 | Nk细胞中对细胞因子诱导的sh2蛋白的抑制 |
| EP4026849A1 (en) * | 2016-09-26 | 2022-07-13 | Ensemble Group Holdings | Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors |
| US11279763B2 (en) | 2016-10-27 | 2022-03-22 | The Regents Of The University Of California | Integrin alpha 9 blockade suppresses lymphatic valve formation and promotes transplant survival |
| CA3048376A1 (en) | 2016-12-27 | 2018-07-05 | Riken | Bmp-signal-inhibiting compound |
| CN109942616A (zh) * | 2019-04-18 | 2019-06-28 | 广东工业大学 | 一种含炔基的芳基酰胺类衍生物及其制备方法和应用 |
| CN114853740B (zh) * | 2021-02-03 | 2023-08-01 | 药雅科技(上海)有限公司 | 炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010130757A1 (en) * | 2009-05-14 | 2010-11-18 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
| JP2010539094A (ja) * | 2007-09-10 | 2010-12-16 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むｖｅｇｆｒインヒビター |
| WO2012022408A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate als fak inhibitoren |
| WO2012036919A2 (en) * | 2010-09-14 | 2012-03-22 | Glaxosmithkline Llc | Combination of braf and vegf inhibitors |
| JP2012511016A (ja) * | 2008-12-05 | 2012-05-17 | アボット・ラボラトリーズ | 癌の治療に使用するためのキナーゼ阻害剤としてのチエノ［３，２−ｃ］ピリジン誘導体 |
| JP5937111B2 (ja) * | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | Ｆａｋ阻害剤 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE50212771D1 (de) * | 2001-10-17 | 2008-10-23 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| EP2367826A4 (en) | 2008-11-06 | 2012-07-04 | Astrazeneca Ab | MODULATORS OF THE PROTEIN -AMYLOID |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| WO2012110774A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
| KR101682417B1 (ko) | 2011-02-25 | 2016-12-06 | 주식회사유한양행 | 다이아미노피리미딘 유도체 및 그의 제조방법 |
| EA027982B1 (ru) | 2012-07-17 | 2017-09-29 | Санофи | Применение ингибиторов vegfr-3 для лечения гепатоклеточной карциномы |
| WO2014027199A1 (en) * | 2012-08-14 | 2014-02-20 | Cancer Therapeutics Crc Pty Ltd | Fak and flt3 inhibitors |
| US9238644B2 (en) * | 2012-08-17 | 2016-01-19 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
| CN103113355B (zh) | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
-
2013
- 2013-08-16 JP JP2015526835A patent/JP2015524825A/ja active Pending
- 2013-08-16 US US13/968,932 patent/US9266864B2/en not_active Expired - Fee Related
- 2013-08-16 CA CA2882270A patent/CA2882270A1/en not_active Abandoned
- 2013-08-16 WO PCT/AU2013/000912 patent/WO2014026242A1/en not_active Ceased
- 2013-08-16 US US14/422,084 patent/US20150225377A1/en not_active Abandoned
- 2013-08-16 HK HK15109686.3A patent/HK1209104A1/xx unknown
- 2013-08-16 AU AU2013302319A patent/AU2013302319A1/en not_active Abandoned
- 2013-08-16 EP EP13829826.0A patent/EP2885292A4/en not_active Withdrawn
- 2013-08-16 CN CN201380052157.2A patent/CN104837835A/zh active Pending
- 2013-08-16 CN CN201710144110.9A patent/CN106986832A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010539094A (ja) * | 2007-09-10 | 2010-12-16 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むｖｅｇｆｒインヒビター |
| JP2012511016A (ja) * | 2008-12-05 | 2012-05-17 | アボット・ラボラトリーズ | 癌の治療に使用するためのキナーゼ阻害剤としてのチエノ［３，２−ｃ］ピリジン誘導体 |
| WO2010130757A1 (en) * | 2009-05-14 | 2010-11-18 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
| WO2012022408A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate als fak inhibitoren |
| WO2012036919A2 (en) * | 2010-09-14 | 2012-03-22 | Glaxosmithkline Llc | Combination of braf and vegf inhibitors |
| JP5937111B2 (ja) * | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | Ｆａｋ阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2882270A1 (en) | 2014-02-20 |
| EP2885292A4 (en) | 2015-07-01 |
| US9266864B2 (en) | 2016-02-23 |
| CN104837835A (zh) | 2015-08-12 |
| CN106986832A (zh) | 2017-07-28 |
| US20150225377A1 (en) | 2015-08-13 |
| US20140080798A1 (en) | 2014-03-20 |
| WO2014026242A1 (en) | 2014-02-20 |
| HK1209104A1 (en) | 2016-03-24 |
| AU2013302319A1 (en) | 2015-02-26 |
| EP2885292A1 (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5937111B2 (ja) | Ｆａｋ阻害剤 | |
| US9856252B2 (en) | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | |
| EP3189048B1 (en) | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors | |
| US9238644B2 (en) | VEGFR3 inhibitors | |
| US9266864B2 (en) | VEGFR3 inhibitors | |
| EP3189041A1 (en) | Tetrahydroisoquinoline derived prmt5-inhibitors | |
| CA3056726A1 (en) | Tricyclic compounds for use in treatment of proliferative disorders | |
| EP3426648A1 (en) | Tetrahydroisoquinolines as prmt5 inhibitors | |
| US10787434B2 (en) | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | |
| CN102656172B (zh) | 8-氧代二氢嘌呤衍生物 | |
| WO2014027199A1 (en) | Fak and flt3 inhibitors | |
| WO2015123722A1 (en) | Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150617 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160816 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160816 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170530 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180109 |